Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Tran

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Nature Reviews. Drug Discovery|November 29, 2023
A call to adapt the regulation of HLA testing for T cell receptor-based therapeuticsMiriam Meyer, Andrea Mahr, Joanna Brewer, et al.
Nature|August 8, 2017
Identification of essential genes for cancer immunotherapyShashank J Patel, Neville E Sanjana, Rigel J Kishton, et al.
Cancer Research|November 30, 2014
Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristicsJoseph G Crompton, Madhusudhanan Sukumar, Rahul Roychoudhuri, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 12, 2026
T-cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trialXiongfei Xu, Haihui Gu, Zhanshan Cha, et al.
Cancer Discovery|June 6, 2019
Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal CancersMaria R Parkhurst, Paul F Robbins, Eric Tran, et al.
The Lancet. Oncology|August 17, 2019
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2024
Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized TrialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR TrialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trialDavid A Palma, Eitan Prisman, Eric Berthelet, et al.
JAMA Oncology|April 28, 2022
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical TrialDavid A Palma, Eitan Prisman, Eric Berthelet, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Nature Reviews. Drug Discovery|November 29, 2023
A call to adapt the regulation of HLA testing for T cell receptor-based therapeuticsMiriam Meyer, Andrea Mahr, Joanna Brewer, et al.
Nature|August 8, 2017
Identification of essential genes for cancer immunotherapyShashank J Patel, Neville E Sanjana, Rigel J Kishton, et al.
Cancer Research|November 30, 2014
Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristicsJoseph G Crompton, Madhusudhanan Sukumar, Rahul Roychoudhuri, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 12, 2026
T-cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trialXiongfei Xu, Haihui Gu, Zhanshan Cha, et al.
Cancer Discovery|June 6, 2019
Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal CancersMaria R Parkhurst, Paul F Robbins, Eric Tran, et al.
The Lancet. Oncology|August 17, 2019
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2024
Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized TrialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR TrialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trialDavid A Palma, Eitan Prisman, Eric Berthelet, et al.
JAMA Oncology|April 28, 2022
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical TrialDavid A Palma, Eitan Prisman, Eric Berthelet, et al.
Pageof 13